BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

SenoSENSE Medical Systems Announces Enrollment Completed in Study of Novel Device to Measure Breast Density


10/25/2012 9:10:40 AM

TORONTO--(Marketwire - October 25, 2012) - SenoSENSE Medical Systems Inc., a medical device company engaged in the development of innovative technologies targeted to reducing the impact of breast cancer, announced today that it has completed enrollment of a 100 patient study evaluating the effectiveness of the company's Electrical Breast Densitometer™ system. The Electrical Breast Densitometer evaluates breast density using a proprietary Densitrode™ sensor and electronics. The density test is painless, emits no radiation, and takes less than a minute. The initial study was undertaken at Timmins and District Hospital under the direction of Principal Investigator Dr. Karina Bukhanov, Breast Radiologist affiliated with Mount Sinai Hospital Marvelle Koffler Breast Centre and Gattuso Rapid Diagnosis Clinic at Princess Margaret Hospital. The results of the first 20 patients enrolled in the study were recently presented at the ASCO Breast Cancer Symposium and show that the technique is accurate and highly reproducible.

"Breast density is one of the major factors in developing breast cancer," noted Dr. Bukhanov. "A woman who has extremely dense breasts is at approximately five times the risk of developing the disease compared to a woman who has breasts with fatty, low-density tissue. Our ability to identify these women will allow us to screen this population more effectively and also permit these women to implement risk prevention techniques."

"The completion of the initial human study evaluating Densitrode™ breast density technology represents an important milestone in advancing an exciting new technology," commented Joel Ironstone, President and Chief Executive Officer of SenoSENSE Medical Systems. "We believe that the Electrical Breast Densitometer offers great promise to identify younger women who are at increased risk of breast cancer and enable proactive intervention to reduce their risk and initiate earlier surveillance in order to identify cancer at an earlier and more treatable stage."

About SenoSENSE Medical Systems Inc.
SenoSENSE Medical Systems is a Toronto, Ontario-based early-stage medical device company developing technology that enables personalized management of breast cancer risk. The company's first product, the Electrical Breast Densitometer, employs proprietary Densitrode™ technology to assess and monitor breast density, the most significant non-genetic risk factor for breast cancer. Breast cancer remains an unsolved problem and represents the most prevalent cause of death in women under the age of 50.


Contact:
Joel Weinstein
Marketing/Corporate Development
SenoSENSE Medical Systems Inc.
(508) 877-9025
Email Contact
www.senosense.com



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES